(IQV) IQVIA Holdings Inc. Bundle
What does IQVIA Holdings do?
IQVIA Holdings Inc. is a healthcare intelligence and clinical research company that connects data, analytics, technology, and outsourced services for the life sciences industry. Its official company overview frames the mission as using analytics, transformative technology, big data resources, and domain expertise to create intelligent connections across healthcare. For a student or investor, the key point is that IQVIA helps biopharmaceutical companies understand markets, run clinical development programs, commercialize products, and use real-world data for evidence and access decisions.
What market does IQVIA serve?
The core customer group is global life sciences: pharmaceutical companies, biotechnology companies, medical-device firms, and other healthcare stakeholders. IQVIA's FY2025 Form 10-K describes more than 10,000 clients in more than 100 countries, product tracking in 97 markets, and more than 1.2 billion unique non-identified patient records. It also places the 2025 addressable opportunity at roughly $335 billion.
Why do healthcare data and clinical execution belong together?
IQVIA's strategic position comes from combining information and services. Data can help identify patients, markets, sites, treatment patterns, and commercial opportunities; clinical execution turns development programs into contracted work and backlog; commercial solutions help clients launch and measure products after approval. The result is a model where the same customer can buy analytics, technology, real-world evidence, trial services, field support, and commercialization tools from one supplier.
How does IQVIA make money?
IQVIA earns revenue by selling services and technology-enabled solutions to healthcare and life sciences customers. In R&D Solutions, contracts commonly cover clinical research services, laboratory testing, real-world evidence, trial execution, and related development activities. In Commercial Solutions, revenue comes from data, analytics, consulting, technology, marketing, commercial operations, and connected-health offerings that help customers understand markets and manage product commercialization.
Which segment generates the most revenue?
R&D Solutions is the larger segment. In Q1 2026, it generated $2.397 billion, or 57.7% of total revenue, while Commercial Solutions generated $1.754 billion, or 42.3%. On a recast FY2025 basis disclosed with the 2026 reporting change, R&D Solutions generated $9.570 billion and Commercial Solutions generated $6.740 billion. That makes clinical development services the largest revenue pool, while commercial data and analytics remain a major profit and differentiation engine.
How does clinical revenue recognition affect the model?
R&D contracts are not simple product sales. Most clinical research contracts contain a single performance obligation, with revenue recognized over time using costs incurred relative to estimated total costs. That makes backlog, bookings, staffing, investigator payments, trial scope, cancellations, and cost-to-complete estimates central to revenue conversion and margin quality.
| Revenue stream | Typical customer need | Revenue logic | Key analytical driver |
|---|---|---|---|
| R&D Solutions | Clinical development, trials, labs, real-world evidence, and regulatory support. | Multi-year service contracts, backlog conversion, reimbursed expenses, and project execution. | Bookings, book-to-bill, backlog conversion, segment margin, and clinical workload. |
| Commercial Solutions | Market measurement, analytics, technology, commercial operations, consulting, and connected health. | Recurring data and analytics relationships, technology-enabled services, and outsourced commercial work. | Client retention, data scale, healthcare privacy compliance, pricing power, and operating leverage. |
| Geographic operations | Global commercialization and clinical support across the Americas, Europe & Africa, and Asia-Pacific. | Local market data, international trials, client budgets, and currency translation. | FY2025 revenue mix: Americas 47.5%, Europe & Africa 31.8%, Asia-Pacific 20.7%. |
Which strategic turning points still shape IQVIA today?
IQVIA's current strategy is best understood as a data-and-services merger thesis. The company combined IMS Health's healthcare information assets with Quintiles' clinical research scale, then repositioned around connected intelligence, real-world data, and integrated development-to-commercialization services.
-
2014IMS Health completed its public-company phase before the later merger; Ari Bousbib led IMS Health through the IPO period and later became IQVIA's chairman and CEO.
-
2016IMS Health and Quintiles completed their merger, creating QuintilesIMS. The merger announcement explains why the combined model joined information, technology, and clinical execution.
-
2017QuintilesIMS became IQVIA, and the NYSE ticker changed to IQV. The name change signaled a broader healthcare intelligence strategy rather than a traditional CRO-only identity.
-
2025FY2025 revenue reached $16.310B, adjusted EBITDA reached $3.788B, and free cash flow reached $2.051B, giving the company scale to fund acquisitions, data investment, technology, and buybacks.
-
2026IQVIA reorganized external reporting into Commercial Solutions and R&D Solutions, moving real-world late-phase offerings into R&D and commercial measurement services into Commercial Solutions.
-
Q1 2026Backlog reached $34.2B and expected next-12-month conversion reached $8.9B, making bookings and backlog conversion central to the near-term thesis.
What did the 2016 merger change?
The merger changed the strategic unit of analysis. The thesis became integration: use healthcare data and analytics to design, recruit, execute, measure, and commercialize healthcare programs. IQVIA's moat is therefore not only trial labor scale; it also includes data, privacy safeguards, technology, therapeutic expertise, and customer relationships.
Why does the 2026 segment reset matter?
The 2026 reset makes the current model easier to read. The company moved Real-World Late Phase and other real-world offerings with FY2025 revenue of $674 million into R&D Solutions and moved former CSMS activity with FY2025 revenue of $788 million into Commercial Solutions. The FY2025 results package that introduced the new presentation provides the recast base: Commercial Solutions at $6.740 billion and R&D Solutions at $9.570 billion, which helps analysts compare Q1 2026 against a cleaner two-segment baseline in the official FY2025 results release.
What did IQVIA's latest quarter show?
The latest official reporting period is Q1 2026, the quarter ended March 31, 2026. IQVIA reported revenue of $4.151 billion, up 8.4% as reported and 6.0% at constant currency, in the Q1 2026 earnings release. The quarter was positive on revenue, bookings, and free cash flow conversion, but operating income growth was held back by higher cost of revenues, restructuring expense, depreciation and amortization, and interest expense.
Revenue growth was healthy, but margins need interpretation
The Q1 2026 Form 10-Q shows cost of revenues at $2.796 billion, or 67.4% of revenue, compared with 66.1% a year earlier. SG&A was $502 million, or 12.1% of revenue, down from 13.3%. SG&A leverage helped, but cost pressure and restructuring limited GAAP operating margin to 12.4%.
| Q1 2026 item | Reported figure | Interpretation |
|---|---|---|
| Revenue | $4.151B | The main top-line signal; growth was 8.4% reported and 6.0% constant currency. |
| Operating income | $514M | GAAP operating margin was 12.4%; D&A and restructuring weigh on GAAP profitability. |
| Adjusted EBITDA | $932M | Adjusted EBITDA grew 5.5%; EBITDA margin was 22.5% for Q1 2026. |
| Net income attributable to IQVIA | $274M | Net margin was 6.6%; interest expense was $192M in the quarter. |
| Free cash flow | $491M | Free cash flow margin was 11.8%; management reported 15% free cash flow growth. |
Why does backlog matter so much?
For R&D Solutions, backlog is the bridge between signed clinical work and future revenue. IQVIA ended Q1 2026 with $34.2 billion of R&D contracted backlog and expected about $8.9 billion to convert into revenue over the next 12 months. Net new bookings were $2.5 billion, the quarter book-to-bill was 1.04x, and the trailing-twelve-month book-to-bill was 1.11x. Those metrics are important because they show whether new work is replacing revenue being delivered.
How financially strong is IQVIA?
IQVIA is financially strong in operating cash generation but meaningfully leveraged. That combination is central to the analysis. The company generates substantial adjusted EBITDA and free cash flow, but it also carries large debt from its acquisition-oriented, asset-intangible-heavy model. The financial question is not whether the business produces cash; it is how much of that cash must support interest, leverage, acquisitions, technology investment, and repurchases.
Cash flow conversion is a real strength
In FY2025, IQVIA generated $2.654 billion of operating cash flow and $2.051 billion of free cash flow. Capital expenditures for property, equipment, and software were $603 million, which implies capital intensity of about 3.7% of FY2025 revenue. In Q1 2026, operating cash flow was $618 million and free cash flow was $491 million, up 9% and 15%, respectively.
Debt is the balance-sheet constraint
The leverage side is just as important. At March 31, 2026, IQVIA reported $1.947 billion of cash and cash equivalents and $15.833 billion of debt, producing net debt of $13.886 billion. Management reported a trailing-twelve-month net leverage ratio of 3.62x adjusted EBITDA. The 2025 filing also shows large acquisition-related intangibles: goodwill of $16.616 billion and other identifiable intangibles of $4.962 billion at December 31, 2025. Those figures do not make the company weak, but they do make debt cost, acquisition integration, amortization, and impairment testing meaningful for valuation.
| Financial strength item | Period | Figure | Investor interpretation |
|---|---|---|---|
| Cash and cash equivalents | March 31, 2026 | $1.947B | Liquidity supports working capital and near-term obligations. |
| Total debt | March 31, 2026 | $15.833B | Debt load is the main balance-sheet pressure point. |
| Net leverage | Trailing twelve months at Q1 2026 | 3.62x adjusted EBITDA | Leverage makes interest rates and refinancing terms important. |
| Share repurchases | Q1 2026 | $552M | Management continued buybacks despite leverage; remaining authorization was $1.217B. |
| Senior notes issuance | FY2025 | $2.000B at 6.250% due 2032 | Debt market access remains important to the capital structure. |
What gives IQVIA a competitive advantage?
The advantage is not a single patent or consumer brand. It is a bundled capability set: global clinical operations, healthcare data rights, non-identified patient data, analytics, technology platforms, privacy safeguards, therapeutic expertise, and life sciences relationships.
Data scale and domain trust are hard to replicate
Healthcare data is valuable only when it is relevant, broad, compliant, and usable for decisions. IQVIA's FY2025 filing refers to product tracking in 97 markets and more than 1.2 billion unique non-identified patient records. Scale matters because it can improve market measurement, site selection, real-world evidence, and commercial targeting. Trust matters because healthcare data is sensitive, regulated, and reputation-sensitive. A vendor that mishandles privacy, cybersecurity, or regulatory obligations can damage both client relationships and the business model.
Which competitors pressure the business?
IQVIA's filing explicitly says the biopharmaceutical services industry is highly competitive and includes large biopharmaceutical services companies, internal customer departments, universities, teaching hospitals, government agencies, smaller specialized providers, and multi-country players. Its TSR peer set includes Charles River Laboratories, Fortrea, ICON, Medpace, S&P Global, Danaher, and Thermo Fisher Scientific. The peer set is useful because it shows IQVIA is compared both with clinical research companies and with information, technology, and life sciences tools businesses.
| Competitive pressure | Examples or source basis | How IQVIA differentiates |
|---|---|---|
| Clinical research organizations | ICON, Fortrea, Medpace, and large service providers. | Global trial capacity plus data, real-world evidence, and commercial analytics. |
| Life sciences tools and lab companies | Thermo Fisher Scientific, Danaher, and Charles River in the peer universe. | IQVIA is less product-instrument focused and more data, analytics, and service-execution focused. |
| Information and analytics providers | Healthcare data, market measurement, and information-services competitors. | The advantage is linking data to clinical, commercial, and real-world execution workflows. |
| Client internal teams | Pharma and biotech companies may run parts of trials, analytics, or commercial operations internally. | Outsourcing remains attractive when global scale, speed, compliance, and specialized technology matter. |
Which KPIs best explain IQVIA's performance?
IQVIA should not be analyzed with a single revenue-growth metric. The useful KPI set combines top-line growth, constant-currency growth, segment profit, backlog conversion, book-to-bill, free cash flow conversion, net leverage, and capital intensity. These metrics connect the income statement, service backlog, cash-flow statement, and balance sheet.
Backlog and book-to-bill explain future revenue visibility
At March 31, 2026, R&D contracted backlog was $34.2 billion, up 7.6% year over year on expected next-12-month conversion. Expected conversion over the next 12 months was $8.9 billion. Q1 2026 net new bookings were $2.5 billion, the quarter book-to-bill was 1.04x, and trailing-twelve-month book-to-bill was 1.11x. A book-to-bill above 1.0x means bookings are exceeding revenue in the period, which supports backlog replenishment.
Margins and cash conversion show execution quality
For a DCF, free cash flow quality matters more than adjusted EPS alone. In Q1 2026, adjusted diluted EPS was $2.90, adjusted net income was $492 million, and free cash flow was $491 million. In FY2025, adjusted diluted EPS was $11.92, adjusted EBITDA was $3.788 billion, and free cash flow was $2.051 billion. If free cash flow conversion weakens while revenue grows, the model becomes less attractive; if conversion remains high while leverage falls, equity value sensitivity can improve.
Who owns IQVIA stock, and what does governance signal?
IQVIA has a conventional public-company ownership profile: one common equity class, large passive and institutional holders, and modest insider ownership rather than founder-family voting control. The latest proxy is useful because it shows both ownership concentration and governance structure. Based on 169,717,664 shares outstanding as of January 31, 2026, the 2026 proxy statement lists Vanguard, BlackRock, and Harris Associates as major holders.
| Holder or group | Shares or stake | Source period | Why it matters |
|---|---|---|---|
| The Vanguard Group | 21,077,827 shares; 12.4% | Proxy table based on shares outstanding at Jan. 31, 2026 | Large passive ownership increases the importance of governance quality and index-fund voting policies. |
| BlackRock | 15,166,087 shares; 8.9% | Proxy table based on shares outstanding at Jan. 31, 2026 | Another major passive holder; the proxy also notes an ordinary-course information-asset license with BlackRock. |
| Harris Associates | 11,753,182 shares; 6.9% | Proxy table based on shares outstanding at Jan. 31, 2026 | An active institutional holder can focus attention on value creation, margins, and capital allocation. |
| Ari Bousbib | 2,421,932 shares; 1.4% | Proxy table based on shares outstanding at Jan. 31, 2026 | The chairman and CEO has a meaningful equity interest but does not control the vote. |
| Directors and executive officers as a group | 2,982,890 shares; 1.7% | Proxy table based on shares outstanding at Jan. 31, 2026 | Governance influence is dispersed; board oversight and institutional voting matter more than insider control. |
What does management structure imply?
Ari Bousbib has served as chairman and CEO since the 2016 merger, which gives strategic continuity to the integration thesis. The governance offset is independent-board structure. IQVIA's official board page and proxy materials indicate that all directors other than the CEO are independent, the company has a Lead Independent Director, and all three standing board committees are composed entirely of independent directors.
Why does ownership matter for capital allocation?
Dispersed institutional ownership tends to emphasize free cash flow, leverage discipline, and transparent capital allocation. IQVIA repurchased $1.244 billion of stock in FY2025 and $552 million in Q1 2026, creating a trade-off between per-share returns, debt reduction, acquisitions, technology investment, and compliance costs.
What opportunities and risks could change IQVIA's outlook?
IQVIA's opportunity set is tied to healthcare complexity: expensive drug development, global trials, rising evidence standards, payer scrutiny, and the need for better commercialization data. The same complexity creates risk through privacy rules, contract cancellations, biotech funding cycles, trial delays, cyber events, and competition.
Which growth drivers are most relevant?
FY2026 guidance points to revenue of $17.150 billion to $17.350 billion and adjusted EBITDA of $3.975 billion to $4.025 billion, including about 150 basis points from acquisitions and about 100 basis points from FX. Backlog conversion, customer budgets, and margin quality still determine the economic value of growth.
What risks appear most material in filings?
The most company-specific risk cluster is regulation around healthcare data, clinical research, and promotional activity. IQVIA processes sensitive patient diagnosis and treatment information, so privacy and data-protection laws can require spending or limit services. Filing language also emphasizes clinical regulation, contract termination, cybersecurity, client consolidation, biotech funding conditions, and leverage.
| Risk or opportunity | Financial line affected | What to monitor |
|---|---|---|
| Clinical outsourcing demand | R&D Solutions revenue and backlog | Book-to-bill, cancellations, trial starts, and next-12-month backlog conversion. |
| Healthcare data and privacy regulation | Commercial Solutions revenue, compliance cost, and reputation | New privacy laws, data-use restrictions, enforcement actions, and security incidents. |
| Customer budget cycles | Revenue growth, bookings, and pricing | Large-pharma R&D budgets, biotech funding availability, and customer consolidation. |
| Debt and interest rates | Interest expense, net income, and equity value | Net leverage, refinancing, credit spreads, and free cash flow after buybacks. |
| Execution and cost estimates | R&D margins and revenue recognition | Trial delays, cost-to-complete changes, investigator costs, and restructuring progress. |
Why does IQVIA matter for valuation and DCF work?
IQVIA is a useful DCF case because reported revenue, adjusted EBITDA, backlog, cash conversion, debt, and amortization all tell different parts of the story. Revenue growth alone is not enough. A model needs to separate Commercial Solutions from R&D Solutions, estimate whether backlog converts into profitable revenue, normalize restructuring and amortization, and test how much free cash flow remains after capital spending, interest, acquisitions, and buybacks.
Which assumptions drive intrinsic-value sensitivity?
The modeling tension is that IQVIA has attractive scale and cash generation, but leverage and acquisition-related intangibles increase execution sensitivity. Higher revenue growth is valuable only if segment margins, working capital, capital spending, and debt control remain disciplined. For comparable-company work, IQVIA screens partly like a CRO, partly like a data vendor, and partly like a healthcare technology-enabled services company.
What is the key takeaway from IQVIA analysis?
IQVIA matters because it sits at the intersection of life sciences R&D outsourcing, healthcare data, analytics, technology, and commercialization support. Q1 2026 showed revenue growth, backlog depth, and strong free cash flow conversion. The constraints are also clear: large debt, heavy regulation, clinical-contract delays or terminations, and intense competition.
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.